Lieve Adriaens

A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors

E. Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother et al. · Clinical Cancer Research · 2015 · 147 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher et al. · Clinical Cancer Research · 2015 · 71 citations

Pharmacy, Oncology, Pharmacology +16

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, John N. Allan, Jon Arnason et al. · Blood · 2019 · 57 citations

Medicine, Hematology, Oncology +17

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Deepu Madduri, Ashley Rosko, Jason Brayer et al. · Blood · 2020 · 57 citations

Medicine, Immunology, Oncology +15

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, Deepu Madduri, Suzanne Lentzsch et al. · Blood · 2019 · 40 citations

Medicine, Hematology, Oncology +16